La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Sartorius Stedim Biotech Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Sartorius Stedim Biotech ha un patrimonio netto totale di €3.9B e un debito totale di €2.8B, che porta il suo rapporto debito/patrimonio netto a 71.7%. Le sue attività totali e le sue passività totali sono rispettivamente €8.1B e €4.1B. L'EBIT di Sartorius Stedim Biotech è €416.9M rendendo il suo rapporto di copertura degli interessi 2.6. Ha liquidità e investimenti a breve termine pari a €454.1M.

Informazioni chiave

71.7%

Rapporto debito/patrimonio netto

€2.81b

Debito

Indice di copertura degli interessi	2.6x
Contanti	€454.10m
Patrimonio netto	€3.92b
Totale passività	€4.14b
Totale attività	€8.07b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( €1.7B ) di DIMP superano le sue passività a breve termine ( €873.8M ).

Passività a lungo termine: Le attività a breve termine di DIMP ( €1.7B ) non coprono le sue passività a lungo termine ( €3.3B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 60.1% ) di DIMP è considerato alto.

Riduzione del debito: Il rapporto debito/patrimonio netto di DIMP è aumentato da 11% a 71.7% negli ultimi 5 anni.

Copertura del debito: Il debito di DIMP è ben coperto dal flusso di cassa operativo ( 25.1% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di DIMP non sono ben coperti dall'EBIT ( 2.6 x copertura).

Sartorius Stedim Biotech Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Insufficient new directors

Investor sentiment deteriorates as stock falls 27%

Insufficient new directors

Upcoming dividend of €0.69 per share

New minor risk - Profit margin trend

Dividend of €0.69 announced

Insufficient new directors

Sartorius Stedim Biotech S.A. has filed a Follow-on Equity Offering in the amount of €1.2 billion.

Sartorius Stedim Biotech S.A. has completed a Follow-on Equity Offering in the amount of €1.2 billion.

Insufficient new directors

Sartorius Stedim Biotech S.A. to Report Nine Months, 2024 Results on Oct 17, 2024

Investor sentiment improves as stock rises 16%

Insufficient new directors

Third quarter 2023 earnings released: EPS: €0.28 (vs €2.22 in 3Q 2022)

Investor sentiment deteriorates as stock falls 16%

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: €1.44 (vs €2.33 in 2Q 2022)

Less than half of directors are independent

Investor sentiment deteriorates as stock falls 15%

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: EPS: €9.51 (vs €4.50 in FY 2021)

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2023

Less than half of directors are independent

Sartorius Stedim Biotech S.A. to Report Fiscal Year 2022 Results on Jan 26, 2023

Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 27, 2023

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: €2.22 (vs €1.60 in 3Q 2021)

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2022

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire Albumedix Ltd. from private investors for approximately £420 million.

Second quarter 2022 earnings released: EPS: €2.33 (vs €1.61 in 2Q 2021)

Less than half of directors are independent

First quarter 2022 earnings released: EPS: €2.93 (vs €1.24 in 1Q 2021)

Sartorius Stedim Biotech S.A. Confirms Earnings Guidance for the Year 2022

Sartorius Stedim Biotech S.A. Approves Dividend for the Fiscal Year 2021

Upcoming dividend of €1.26 per share

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sartorius Stedim Biotech S.A. Updates Earnings Guidance for the Year 2022

Sartorius Stedim Biotech S.A. Recommends Dividend

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of chromatography equipment division from Novasep Holding SAS.

Sartorius Stedim Biotech Provides Earnings Guidance for the Full Year 2022

Third quarter 2021 earnings released: EPS €1.60 (vs €1.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS €1.56 (vs €0.73 in 2Q 2020)

Sartorius Stedim Biotech S.A. Raises Forecast for the Full Year 2021

First quarter 2021 earnings released: EPS €1.24 (vs €0.81 in 1Q 2020)

Sartorius Stedim Biotech Raises Consolidated Sales Guidance for 2021

Sartorius Stedim Biotech Increases Earnings Guidance for 2021

Full year 2020 earnings released: EPS €3.88 (vs €2.54 in FY 2019)

Revenue misses expectations

New 90-day high: €362

Sartorius Stedim Biotech S.A. to Report Nine Months, 2021 Results on Oct 20, 2021

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) signed an agreement to acquire chromatography equipment division from Novasep Holding SAS.

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of BIA Separations d.o.o.

Sartorius Stedim Biotech S.A. to Report Q1, 2021 Results on Apr 21, 2021

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire BIA Separations d.o.o. for ?€360 million.

Sartorius Aktiengesellschaft (XTRA:SRT) and Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of certain businesses from Danaher Corporation (NYSE:DHR).

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane